Saol Therapeutics - Baclofen Franchise - Ownership and Business Overview

Life ScienceCompany

Saol Therapeutics - Baclofen Franchise Ownership

Who owns Saol Therapeutics - Baclofen Franchise?

Saol Therapeutics - Baclofen Franchise is owned by Amneal Pharmaceuticals. It was acquired on January 5, 2022.

Saol Therapeutics - Baclofen Franchise Business Overview

Where is Saol Therapeutics - Baclofen Franchise headquartered?

Saol Therapeutics - Baclofen Franchise is headquartered in Roswell, Georgia.

What sector is Saol Therapeutics - Baclofen Franchise in?

Saol Therapeutics - Baclofen Franchise is a life science company.

Life Science M&A Summary in 2022

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2022. The largest life science acquisition in 2022 was Horizon Therapeutics Public Limited Company - which was acquired by Amgen for $27.8B.

Join Mergr to view all 294 acquisitions of life science companies in 2022, including 37 acquisitions by private equity firms, and 257 by strategics.

Saol Therapeutics - Baclofen Franchise

Roswell, Georgia
United States,

Saol Therapeutics' Baclofen Franchise is a pipeline product under development. Lioresal® is an intrathecal baclofen product delivered through an implantable intrathecal pump for use in the management of severe spasticity of cerebral or spinal origin for the institutional market. LYVISPAHTM is a baclofen oral granules (5, 10, and 20 mg) specialty product recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of spasticity.


 Subscribe to unlock this and 207,814
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 200K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.